Ozempic Regulatory Status: US, EU, Canada, and UK Approvals Explained

How Ozempic Works: Mechanism of Action

Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, driving glucose-dependent insulin release, suppressing glucagon, and slowing gastric emptying. The result is lower post-meal blood glucose and, as a secondary effect, reduced appetite and caloric intake [1].

GLP-1 Receptor Binding and Glucose Control

Natural GLP-1 has a plasma half-life of roughly two minutes because dipeptidyl peptidase-4 (DPP-4) degrades it rapidly [2]. Novo Nordisk modified the semaglutide backbone with a C18 fatty-acid side chain attached via a linker, which allows non-covalent albumin binding. This structural change extends the half-life to approximately seven days, making once-weekly dosing achievable [3].

Insulin secretion is strictly glucose-dependent with semaglutide. Below roughly 70 mg/dL, GLP-1 receptor stimulation does not meaningfully drive additional insulin release, which explains the low hypoglycemia risk seen in monotherapy trials [4].

Central Appetite Suppression

GLP-1 receptors in the hypothalamus and brainstem regulate satiety signaling. Semaglutide crosses the blood-brain barrier at the circumventricular organs and reduces activity in appetite-promoting circuits [5]. This central action is dose-dependent, which is why higher-dose formulations (Wegovy at 2.4 mg) produce greater weight loss than the diabetes doses (0.5 to 2.0 mg) studied in the SUSTAIN program.

Cardiovascular Mechanisms

Beyond glycemia, semaglutide reduces systolic blood pressure by roughly 3 to 6 mmHg, lowers C-reactive protein, and modestly reduces LDL-C [6]. These pleotropic effects contributed to the cardiovascular outcomes data that expanded the label in each jurisdiction.

United States: FDA Approval History and Current Label

The FDA approved Ozempic on December 5, 2017, under NDA 209637 for adults with type 2 diabetes to improve glycemic control alongside diet and exercise [7]. The initial approved doses were 0.5 mg and 1.0 mg once weekly.

2021 Cardiovascular Label Expansion

On January 12, 2021, FDA approved a label update adding the indication to reduce the risk of major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, or CV death) in adults with type 2 diabetes and established cardiovascular disease. This expansion rested on the SUSTAIN-6 trial (N=3,297), in which semaglutide reduced the primary MACE endpoint by 26% versus placebo (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for non-inferiority, P=0.02 for superiority) [8].

2022 Dose Expansion to 2.0 mg

FDA approved the 2.0 mg once-weekly dose in March 2022, making it the highest dose available in the Ozempic formulation. The sNDA was supported by the SUSTAIN FORTE trial (N=961), where 2.0 mg lowered HbA1c by 2.2 percentage points versus 1.9 percentage points for 1.0 mg at 40 weeks [9]. The 2.0 mg dose is not interchangeable with Wegovy 2.4 mg despite sharing the same active molecule; the delivery device and drug concentration differ.

Current US Prescribing Field

Ozempic carries a black-box warning for thyroid C-cell tumors based on rodent data [10]. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in those with multiple endocrine neoplasia type 2 (MEN 2). Prescribers must register patients in the REMS program for these contraindications. Off-label prescribing for weight loss occurs frequently in clinical practice, but the FDA label does not authorize this use at the 0.5 to 2.0 mg doses.

European Union: EMA Approval and CHMP Review

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion on January 25, 2018, and the European Commission issued the formal marketing authorization on February 8, 2018, under the brand name Ozempic [11]. The authorized indication mirrors the US label: adjunct to diet and exercise for glycemic control in adults with insufficiently controlled type 2 diabetes mellitus.

EU Cardiovascular Indication

The EMA label includes the cardiovascular risk reduction indication for patients with type 2 diabetes and established cardiovascular disease, consistent with SUSTAIN-6 data [8]. The CHMP assessment report specifically noted that the cardiovascular benefit was observed irrespective of baseline HbA1c, body weight, or diabetes duration, which broadened the population the benefit applies to [12].

EU Shortage and Supply Monitoring

Between 2022 and 2024, the EMA listed Ozempic as a medicine under supply shortage monitoring due to demand driven substantially by off-label weight-loss prescribing. The EMA's shortage page noted that this created access problems for patients using it for its authorized indication [13]. Several EU member states, including Germany and Denmark, implemented prescription restriction measures for off-label use during peak shortage periods.

Dose Availability in the EU

The EU label authorizes 0.5 mg, 1.0 mg, and 2.0 mg doses, matching the US range after Novo Nordisk sought the same 2.0 mg expansion with the EMA. The starting dose is 0.25 mg once weekly for four weeks (a sub-therapeutic dose used only for tolerability), escalating to 0.5 mg, then to 1.0 mg or 2.0 mg based on glycemic response and tolerability.

Canada: Health Canada Approval and NOC

Health Canada issued a Notice of Compliance (NOC) for Ozempic on January 4, 2018, under manufacturer Novo Nordisk Canada Inc. The approved indication is as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [14].

Canadian Cardiovascular Label

Health Canada updated the Ozempic product monograph to include the cardiovascular risk reduction claim after reviewing SUSTAIN-6 data, consistent with approvals in other jurisdictions [8]. The Canadian product monograph specifies that the cardiovascular benefit applies specifically to patients with established atherosclerotic cardiovascular disease, not to those with multiple risk factors alone.

Health Canada Drug Shortages

Canada experienced Ozempic shortages from late 2022 through 2023. Health Canada listed Ozempic on its drug shortage database and worked with Novo Nordisk to manage supply [15]. The shortage was attributed largely to off-label use for obesity, given that Wegovy did not receive Canadian approval until November 2023.

Reimbursement Status in Canada

Public drug plans vary by province. As of mid-2025, most provincial formularies list Ozempic for type 2 diabetes with or without additional criteria. Private insurer coverage is more broadly available. Neither provincial nor federal plans routinely cover off-label weight-loss use at these doses.

United Kingdom: MHRA Approval and Post-Brexit Regulation

The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorization for Ozempic on January 10, 2019 [16]. The authorization was initially granted through the EU procedure while the UK was still in the EU, and was transitioned to a UK marketing authorization following Brexit under the terms of the Withdrawal Agreement.

NICE Guidance and NHS Prescribing

The National Institute for Health and Care Excellence (NICE) issued guidance TA572 in February 2019 recommending Ozempic as an option for treating type 2 diabetes in adults when metformin is inappropriate or not tolerated, or in combination with other antidiabetics [17]. NICE cited the cost-effectiveness analysis and clinical data including SUSTAIN-7, which compared semaglutide directly against dulaglutide (another GLP-1 RA) and demonstrated numerically superior HbA1c reductions and weight loss [18].

SUSTAIN-7 Evidence Underpinning UK Approval

SUSTAIN-7 (N=1,201) was a 40-week, head-to-head trial comparing semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg in adults with type 2 diabetes on metformin [18]. Semaglutide 1.0 mg reduced HbA1c by 1.9 percentage points versus 1.4 percentage points for dulaglutide 1.5 mg (P<0.001). Body weight fell by 6.5 kg with semaglutide 1.0 mg versus 3.0 kg with dulaglutide 1.5 mg (P<0.001). These head-to-head data were central to the NICE cost-effectiveness model because they allowed direct comparison without cross-trial adjustment.

UK Shortage Notices

The MHRA issued shortage notification communications for Ozempic in 2023 and again in 2024, citing sustained demand pressure [19]. NHS England guidance asked prescribers to prioritize patients with established type 2 diabetes over initiating new prescriptions, particularly for off-label indications.

Comparing Regulatory Status Across Jurisdictions

The four major regulatory decisions share more similarities than differences, but the details matter for clinical practice.

| Jurisdiction | Approval Date | Approved Doses | CV Indication | Weight-Loss Approval | |---|---|---|---|---| | USA (FDA) | Dec 5, 2017 | 0.5, 1.0, 2.0 mg | Yes (T2D + CVD) | No | | EU (EMA) | Feb 8, 2018 | 0.5, 1.0, 2.0 mg | Yes (T2D + CVD) | No | | Canada (Health Canada) | Jan 4, 2018 | 0.5, 1.0, 2.0 mg | Yes (T2D + CVD) | No | | UK (MHRA) | Jan 10, 2019 | 0.5, 1.0, 2.0 mg | Yes (T2D + CVD) | No |

All four agencies require Ozempic to be prescribed by, or under the supervision of, a physician or authorized prescriber. All four labels carry thyroid tumor risk language derived from the same rodent carcinogenicity studies [10]. None authorize the 0.5 to 2.0 mg formulation for chronic weight management; that use is off-label in all four jurisdictions.

The Evidence Base That Drove Four Approvals

SUSTAIN Clinical Program Overview

The SUSTAIN program comprised ten phase 3 trials evaluating semaglutide 0.5 mg and 1.0 mg (and later 2.0 mg) across diverse patient populations. The FDA, EMA, Health Canada, and MHRA all reviewed overlapping packages from this program, which is why the approval timelines cluster within 13 months of each other [20].

SUSTAIN-1 through SUSTAIN-5 established efficacy versus placebo and active comparators (sitagliptin, exenatide ER, insulin glargine) across HbA1c reduction and weight outcomes [21]. SUSTAIN-6 established cardiovascular non-inferiority and superiority. SUSTAIN-7 provided the head-to-head dulaglutide comparison central to NICE's TA572.

Key Efficacy Data Points

In SUSTAIN-7 (N=1,201), semaglutide 1.0 mg produced 6.5 kg mean weight loss over 40 weeks versus 3.0 kg for dulaglutide 1.5 mg [18]. The trial also reported that 66% of semaglutide 1.0 mg patients achieved HbA1c <7.0% versus 44% of dulaglutide 1.5 mg patients (P<0.001) [18].

The SUSTAIN-6 cardiovascular outcomes trial (N=3,297, median follow-up 2.1 years) found that semaglutide reduced the combined MACE endpoint to 6.6% versus 8.9% in the placebo arm, representing an absolute risk reduction of 2.3 percentage points [8].

Safety Data Across Programs

Across the SUSTAIN program, nausea affected 15 to 20% of semaglutide-treated patients, predominantly during dose escalation, and was the most common reason for discontinuation [20]. Serious hypoglycemia was rare in monotherapy (incidence <1%) given the glucose-dependent insulin mechanism [4]. Pancreatitis rates were numerically similar between semaglutide and comparator arms in pooled analyses, though the label carries a precautionary warning [22].

The FDA, EMA, Health Canada, and MHRA all concluded that the cardiovascular and glycemic benefits outweigh the risks in the approved population after reviewing the same core safety dataset.

Off-Label Use for Weight Loss: What the Regulations Actually Say

None of the four agencies have approved Ozempic at its current doses for weight management in people without type 2 diabetes. Wegovy (semaglutide 2.4 mg) received FDA approval for chronic weight management in June 2021 and EMA authorization in January 2022, followed by Health Canada approval in November 2023 [23].

Prescribing Ozempic off-label for weight loss is legal in each jurisdiction under the respective frameworks for off-label prescribing, but it carries specific professional and liability implications. The American Diabetes Association's 2024 Standards of Care state: "GLP-1 receptor agonists with proven cardiovascular benefit are recommended for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk" [24]. The guideline does not endorse the use of diabetes-dose semaglutide for weight management in people without diabetes as a first-line approach.

Prescribing Ozempic in 2025: What Clinicians Need to Know

Starting and Titrating the Dose

The standard titration across all four jurisdictions is: 0.25 mg once weekly for 4 weeks (tolerability phase, not therapeutic), then 0.5 mg for at least 4 weeks, then optional escalation to 1.0 mg, then optional escalation to 2.0 mg based on response [7]. Slower titration (extending each step to 8 weeks) reduces nausea without compromising long-term glycemic outcomes, based on clinical experience and post-marketing data.

Contraindications Common to All Labels

All four labels contraindicate Ozempic in patients with:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia type 2 (MEN 2)
• Known hypersensitivity to semaglutide or any excipient

Pregnancy is a contraindication in the EU, Canada, and UK labels. The FDA label advises discontinuation at least two months before a planned pregnancy due to the long half-life.

Drug Interactions and Special Populations

Semaglutide slows gastric emptying and may reduce the absorption rate (though generally not the total absorption) of orally administered drugs. Clinicians should monitor patients on narrow-therapeutic-index oral drugs [25]. Renal impairment does not require dose adjustment based on pharmacokinetic data; semaglutide is not renally eliminated [3]. Hepatic impairment data are limited, but no dose adjustment is currently specified in the label.

Storage and Handling Across Markets

All four markets supply Ozempic in pre-filled, disposable injection pens. Before first use, pens are stored refrigerated (2 to 8°C). After first use, pens may be kept at room temperature (<30°C) for up to 56 days. Each jurisdiction's label specifies these parameters identically, reflecting the same product formulation reviewed by all four agencies [7].